uniQure reported their financial results for the second quarter of 2017.
uniQure N.V. (NASDAQ:QURE) reported their financial results for the second quarter of 2017.
As quoted in the press release:
“We had a highly productive second quarter and past few weeks in which we announced substantial progress in advancing our lead program in hemophilia B through commercial-scale manufacturing and CMC accomplishments, regulatory preparation and the receipt of broader patent protection around our insect-cell platform technology,” stated Matthew Kapusta, chief executive officer of uniQure.
“We presented long-term clinical data in patients with severe hemophilia B demonstrating safety and durable clinical benefits, as well as the potential to treat nearly all patients suffering from this life-changing disorder. We now have full, unencumbered global rights to our hemophilia B program creating value for shareholders and opening the door to new potential opportunities, and we are advancing our Huntington’s disease program into an IND-enabling toxicology study in the fall,” he added. “Furthermore, based on recent encouraging data, uniQure and Bristol-Myers Squibb intend to advance our S100A1 product candidate into additional preclinical studies, including a therapeutic heart failure study that we expect to initiate as soon as possible. We are embarking on a very busy and equally productive second half of the year, and we look forward to providing additional company updates.”